Xenetic Biosciences (XBIO)
3.00
-0.08 (2.60%)
Upcoming Events
Latest Headlines
Xenetic Biosciences partner gets Israeli approval for lymphoma study
June 4, 2026 8:41 AM - StreetInsider
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination
June 4, 2026 8:41 AM - StreetInsider
Xenetic Biosciences presents DNase I data at ASCO 2026 meeting
June 1, 2026 9:03 AM - StreetInsider
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026 9:02 AM - StreetInsider
Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC
May 29, 2026 4:05 PM - SEC Filing
Form SCHEDULE 13G/A Xenetic Biosciences, Filed by: RENAISSANCE TECHNOLOGIES LLC
May 14, 2026 4:48 PM - SEC Filing
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026 8:07 AM - StreetInsider
Form 8-K Xenetic Biosciences, For: May 13
May 13, 2026 8:05 AM - SEC Filing
Form 10-Q Xenetic Biosciences, For: Mar 31
May 12, 2026 4:31 PM - SEC Filing
Form 10-K/A Xenetic Biosciences, For: Dec 31
April 24, 2026 5:15 PM - SEC Filing
Form 8-K Xenetic Biosciences, For: Apr 21
April 24, 2026 5:01 PM - SEC Filing
Form 4 Xenetic Biosciences, For: Apr 21 Filed by: PARSLOW JAMES F
April 23, 2026 7:21 PM - SEC Filing
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 22, 2026 9:00 AM - StreetInsider
Form 8-K Xenetic Biosciences, For: Mar 13
March 13, 2026 8:00 AM - SEC Filing
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026 8:00 AM - StreetInsider
Full Article List
